Sunitinib versus Pazopanib Dilemma in Renal Cell Carcinoma: New Insights into the In Vitro Metabolic Impact, Efficacy, and Safety

Sunitinib versus Pazopanib Dilemma in Renal Cell Carcinoma: New Insights into the In Vitro Metabolic Impact, Efficacy, and Safety

Sunitinib and pazopanib are tyrosine kinase inhibitors (TKIs) used as first-line therapy for metastatic renal cell carcinoma (RCC). Although these TKIs are associated with similar survival outcomes, some differences have been reported in their safety profiles. In this work, traditional toxicological...

Full description

Bibliographic Details
Main Authors: Filipa Amaro, Carolina Pisoeiro, Maria João Valente, Maria de Lourdes Bastos, Paula Guedes de Pinho, Márcia Carvalho, Joana Pinto
Format: Article
Language:English
Published: MDPI AG 2022-08-01
Series:International Journal of Molecular Sciences
Subjects:
metastatic renal cell carcinoma
tyrosine kinase inhibitors
toxicity
oxidative stress
metabolomics
<sup>1</sup>H NMR spectroscopy
Online Access:https://www.mdpi.com/1422-0067/23/17/9898

Internet

https://www.mdpi.com/1422-0067/23/17/9898

Similar Items